Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0120 for Desensitization in Highly Sensitized ESKD Patients Awaiting Kidney Transplant
NCT07350837Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC012 in end-stage kidney disease (ESKD), sponsored by Tongji Hospital. Primary endpoints: Incidence of treatment-related adverse events at 3 years and Occurrence of Dose-Limiting Toxicities at 3 years. Started Jan 2026; status: recruiting.
02
Drugs
GC012
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NCT07350837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07350837.